Skip to main content
Industry News
Rolling submission starts for CTI BioPharma's pacritinib
10/14/2020

CTI BioPharma has initiated the rolling market application submission with the FDA to seek its approval for pacritinib as a treatment for patients with myelofibrosis who have severe thrombocytopenia. Pre-commercial activities have begun and planning is underway for a 2021 commercial launch, according to the company.

Full Story: